Despite current therapies, renal cell carcinoma (RCC) is often lethal. Many factors influence outcomes, including stage, grade, subtype, necrosis, and molecular attributes. Prognosis can be difficult to determine. Comprehensive staging strategies that incorporate multiple patients and tumor factors are necessary to predict survival accurately and optimize research strategies. Recently designed algorithms allow for convenient and up-to-date estimates of outcome in this rapidly evolving field.
Rexahn Pharmaceuticals, Inc., of Rockville, Md., has announced that it has received approval to begin a phase II study for its lead oncology compound, Archexin (formerly known as RX-0201), in patients with advanced renal cell carcinoma.
SAN DIEGO—Stereotactic radiosurgery produces early and durable responses in renal cell carcinoma (RCC) patients with either previously untreated spinal metastases or spinal metastases that have recurred after prior radiotherapy, researchers announced here at the 2007 Annual Meeting of the American Academy of Orthopedic Surgeons.
The FDA issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs). The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).